§ Federal grant opportunity · PAR-25-227
Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)
National Institutes of Health is accepting applications for Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional). The deadline is January 7, 2028 and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- January 7, 2028
- Award range
- Award amount not published
- Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- Geography
- United States
- Focus areas
- Health, Human Services
- Opportunity number
- PAR-25-227
Program overview
The purpose of this Notice of Funding Opportunity (NOFO) encourages applications that will expand knowledge of the natural history of disorders that currently are, or may become, part of statewide newborn screening programs. A comprehensive understanding of the natural history of a condition is necessary to facilitate appropriate interventions for infants identified by newborn screening. Characterization of the sequence and timing of symptom development provides information crucial for developing targeted, age-appropriate treatments and for establishing a baseline against which to assess novel interventions. In addition, for some conditions, establishment of genotype-phenotype correlations may facilitate prediction of the clinical course; for others, identification of modifying genetic, epigenetic, or environmental factors may enhance understanding of clinical outcomes. Comprehensive data on the natural history of a condition will facilitate the fields ability to: 1) identify the underlying biological mechanisms; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the condition; 3) improve diagnostic accuracy; 4) facilitate clinical trials by providing comprehensive natural history data; 5) prevent, manage, and treat symptoms and complications of the condition; 6) furnish physicians and families with needed support and predictive information about the condition; and 7) establish data collection systems or patient registries to collect longitudinal data (e.g., child/family outcomes following newborn screening).
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before January 7, 2028, allowing time for registration and validation.
Related grant opportunities
- Laboratories to Optimize Digital Health (R01 Clinical Trial Required)
- Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
- NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)
- Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.